Hugo Arellano-Santoyo, PhD

Senior Director, Corporate Development

Hugo Arellano-Santoyo is a Senior Director of Corporate Development at Raven. Hugo’s primary responsibility is to focus on new company creation. Prior to Raven, Hugo was a Principal and Senior Associate at Third Rock Ventures where he worked on company creation and investments across various therapeutic areas, helping build companies such as CLASP Therapeutics. Prior to Third Rock, Hugo was at the Novartis Venture Fund working on the investment team. Before that, he was at Novartis where he collaborated with the NIBR and Corporate Strategy teams on a number of projects and was in the research organization in the Chemical Biology and Therapeutics group. Hugo holds a PhD in Biological and Biomedical Sciences from Harvard University, a MS in Molecular and Cellular Biology (Biophysics) from the University of Washington, and a BS in Physics from Princeton University.